Prestige Consumer Healthcare Inc.PBH财报
NYSE · 医疗保健 · 药物制剂
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
PBH 2026财年Q3 Key Financial Metrics
营收
$283.4M
毛利润
$157.4M
营业利润
$82.5M
净利润
$46.7M
毛利率
55.5%
营业利润率
29.1%
净利率
16.5%
同比增长
-2.4%
EPS
$0.97
Prestige Consumer Healthcare Inc. 2026财年Q3 财务摘要
Prestige Consumer Healthcare Inc. 2026财年Q3营收 $283.4M（同比下降 2.4%），净利润 $46.7M（同比下降 23.5%）（净利率 16.5%）。销售成本 $126.1M，运营费用 $74.9M。
核心财务指标
| 总营收 | $283.4M |
|---|---|
| 净利润 | $46.7M |
| 毛利率 | 55.5% |
| 营业利润率 | 29.1% |
| 报告期 | 2026财年Q3 |
营收拆解
Prestige Consumer Healthcare Inc. 2026财年Q3营收 $283.4M 共来自 9 个业务板块，最大板块 Womens Health 贡献 $51.8M（占 18.3%）。
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Womens Health | $51.8M | 18.3% |
| International OTC Healthcare | $47.7M | 16.8% |
| Gastrointestinal | $44.2M | 15.6% |
| Eye And Ear Care | $35.2M | 12.4% |
| Dermatologicals | $27.6M | 9.7% |
| Analgesics | $26.7M | 9.4% |
| Oral Care | $23.5M | 8.3% |
| Cough And Cold | $23.0M | 8.1% |
| Other Otc | $3.6M | 1.3% |
Prestige Consumer Healthcare Inc. 分部营收 — 季度趋势
Prestige Consumer Healthcare Inc. 过去 4 个季度各业务板块营收走势，展示 Womens Health和International OTC Healthcare 等业务的变化。
| 业务分部 | 2026财年Q3 | 2026财年Q2 | 2026财年Q1 | 2025财年Q4 |
|---|---|---|---|---|
| Womens Health | $51.8M | $50.6M | $51.6M | $57.8M |
| International OTC Healthcare | $47.7M | $43.4M | $37.0M | $47.6M |
| Gastrointestinal | $44.2M | $46.4M | $43.7M | $46.2M |
| Eye And Ear Care | $35.2M | $29.4M | $27.8M | $40.5M |
| Dermatologicals | $27.6M | $32.8M | — | $27.0M |
Prestige Consumer Healthcare Inc. 年度营收
Prestige Consumer Healthcare Inc. 历年营收汇总，含各年度总量（例如 2025 年营收为 $1.1B）
Prestige Consumer Healthcare Inc. 季度营收与净利润历史
Prestige Consumer Healthcare Inc. 最近 8 个季度的营收、净利润及同比增速
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| 2026财年Q3 | $283.4M | -2.4% | $46.7M | 16.5% |
| 2026财年Q2 | $274.1M | -3.4% | $42.2M | 15.4% |
| 2026财年Q1 | $249.5M | -6.6% | $47.5M | 19.0% |
| 2025财年Q4 | $296.5M | +7.0% | $50.1M | 16.9% |
| 2025财年Q3 | $290.3M | +2.7% | $61.0M | 21.0% |
| 2025财年Q2 | $283.8M | -0.9% | $54.4M | 19.2% |
| 2025财年Q1 | $267.1M | -4.4% | $49.1M | 18.4% |
| 2024财年Q4 | $277.0M | -3.1% | $49.5M | 17.9% |
利润表
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $277.0M | $267.1M | $283.8M | $290.3M | $296.5M | $249.5M | $274.1M | $283.4M |
| 同比增长 | -3.1% | -4.4% | -0.9% | 2.7% | 7.0% | -6.6% | -3.4% | -2.4% |
资产负债表
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $3.32B | $3.31B | $3.32B | $3.33B | $3.40B | $3.43B | $3.44B | $3.49B |
| 总负债 | $1.66B | $1.63B | $1.59B | $1.54B | $1.57B | $1.58B | $1.62B | $1.67B |
| 股东权益 | $1.66B | $1.68B | $1.73B | $1.79B | $1.83B | $1.86B | $1.82B | $1.83B |
现金流量表
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $66.9M | $54.8M | $69.8M | $65.1M | $61.8M | $79.0M | $57.5M | $78.3M |